High Authority for Health (HAS) announced in a statementon Tuesday, September 20, after granting permission to use three Covid-19 vaccines adapted to the Omicron variant for a new booster vaccination campaign planned for the fall and linked to the influenza campaign.
This new booster dose will be recommended to people at risk of severe form, their companions and carers. HAS recommends “indifferently one of the three bivalent vaccines” – two developed by Pfizer-BioNTech, the third by Moderna – recently validated by the European Medicines Agency.
“Based on the available data and in an epidemic context marked by the majority circulation of the BA.5 subvariant”HAS recommends using “best” one of these vaccines, all messenger RNA, for the new fall booster. This recommendation applies regardless of the Covid vaccine that the person has already received.
Vaccines updated every year
“Like seasonal flu vaccines, which are updated annually to account for the viruses most likely to circulate during the winter, bivalent mRNA vaccines are not new vaccines, but vaccines adapted to circulating strains”emphasizes HAS in its press release.
These are the Moderna and Pfizer-BioNTech vaccines targeting the original strain and variant BA.1 from Omicron and the Pfizer-BioNTech vaccine targeting the original strain and subvariants BA.4 and BA.5 from Omicron.
HAS also stands by its recommendation to combine the Covid-19 booster vaccination campaign with the flu vaccination, which will start on 18 October. A simultaneous injection or the same day of both vaccines is possible, he recalls.
“Immediately and because the number of infection cases started to rise again for several days”This health authority recommends not postponing the second booster dose for people over 60 and under 60 at risk of severe form who did not receive it within the recommended time frame. It resembles the effectiveness of current vaccines (monovalent) against severe forms of Covid-19.